Pancreatic Endoderm Differentiation via Small Molecule Combinations
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for differentiating pluripotent stem cells into pancreatic cells are inefficient, particularly in generating pancreatic endoderm cells that co-express PDX1 and NKX6.1, which are crucial for producing insulin-producing beta cells, with existing protocols only achieving a modest fraction of double-positive cells and failing to produce fully mature beta cells in vitro.
Innovation Solution
Exposing definitive endoderm cells to a combination of BMP inhibitors, kinase inhibitors such as 1,9-pyrazoloanthrone or its isomers, and retinoic acid receptor agonists like AM580, with specific compounds like LDN-193189 and JNK inhibitor II, to enhance the differentiation into pancreatic cell precursors that co-express PDX1 and NKX6.1, thereby improving the efficiency and homogeneity of the pancreatic cell population.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional differentiation protocols are used, then pancreatic cells can be generated, but the fraction of NKX6.1/PDX1 double positive cells remains modest and fully mature beta cells cannot be produced
Solution Approach 1:
The patent applies parameter changes by systematically varying chemical concentrations, treatment durations, and sequential timing of small molecule exposures during differentiation. This includes optimizing the concentration and timing of BMP inhibitors, kinase inhibitors, and retinoic acid receptor agonists to achieve optimal pancreatic endoderm formation and beta cell maturation
Solution Approach 2:
The differentiation protocol is segmented into distinct sequential stages: definitive endoderm formation, pancreatic endoderm differentiation, and beta cell maturation. Each stage uses specific small molecule combinations and durations, allowing precise control over cell fate decisions and enabling progressive accumulation of double positive cells while achieving functional maturity
2Productivity
If existing differentiation protocols are applied, then some pancreatic cells are produced, but the efficiency and homogeneity of the pancreatic cell population are insufficient
Solution Approach 1:
The protocol applies preliminary action by pre-treating cells with specific small molecules during definitive endoderm formation and pancreatic endoderm transition stages. This preliminary exposure to BMP inhibitors and kinase inhibitors primes the cells for subsequent maturation treatments, ensuring efficient and homogeneous differentiation outcomes
Solution Approach 2:
The differentiation process maintains continuous useful action through sequential and overlapping treatment phases where small molecules are applied in a continuous timeline without gaps. This ensures uninterrupted signaling pathways and consistent differentiation pressure, resulting in high efficiency and uniform cell population
Data Source
Figure 1
Figure 2
Figure 3
AI summary
A method of producing pancreatic cells or pancreatic cell precursors expressing at least 5% PDX1/NKX6.1 double positive, comprising exposing definitive endoderm cells to an effective amount of one or more small molecules, to differentiate the human definitive endoderm cells into the pancreatic cells or pancreatic cell precursors. The present invention also relates to pancreatic endoderm cells produced by said methods and uses of said pancreatic endoderm cells.